● Qurient is
a leading R&D based clinical stage biotechnology company in Korea, listed in KOSDAQ (118150). Main focus is on first-in-class small molecule therapeutics in oncology and inflammation TA. Qurient has two programs in clinical development and one program in the IND enabling stage. Q301 is a topical leukotriene inhibitor for atopic dermatitis in a Phase 2b clinical trial in the United States. Q702 is a Axl/Mer/CSF1R triple inhibitor for immune-oncology and drug resistant non-small cell lung cancer, licensed from Max Planck Innovation and Lead Discovery Center in Germany. Telacebec (Q203), which just completed Phase 2a clinical trial, was licensed from Institute of Pasteur in Korea. Qurient is a virtual company doing most of its R&D work through a wide range of international network, now seeking talents to bring the company to the next level.
For more info, please visit www.qurient.com.
New recruit will be eligible for stock option plan to grow with the company
● Job Position